+

WO2002015977A3 - Methodes et compositions pour traiter des maladies liees a l'ige au moyen d'inhibiteurs du nnt-1 - Google Patents

Methodes et compositions pour traiter des maladies liees a l'ige au moyen d'inhibiteurs du nnt-1 Download PDF

Info

Publication number
WO2002015977A3
WO2002015977A3 PCT/US2001/025906 US0125906W WO0215977A3 WO 2002015977 A3 WO2002015977 A3 WO 2002015977A3 US 0125906 W US0125906 W US 0125906W WO 0215977 A3 WO0215977 A3 WO 0215977A3
Authority
WO
WIPO (PCT)
Prior art keywords
nnt
inhibitors
methods
compositions
treating
Prior art date
Application number
PCT/US2001/025906
Other languages
English (en)
Other versions
WO2002015977A2 (fr
Inventor
Giorgio Senaldi
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to MXPA03001434A priority Critical patent/MXPA03001434A/es
Priority to CA002419274A priority patent/CA2419274A1/fr
Priority to JP2002520896A priority patent/JP2004513081A/ja
Priority to EP01962255A priority patent/EP1309374A2/fr
Priority to AU2001283451A priority patent/AU2001283451A1/en
Publication of WO2002015977A2 publication Critical patent/WO2002015977A2/fr
Publication of WO2002015977A3 publication Critical patent/WO2002015977A3/fr
Priority to AU2005232321A priority patent/AU2005232321A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouvelles méthodes et compositions permettant de traiter des maladies liées à l'IgE au moyen d'inhibiteurs du NNT-1. Dans un mode de réalisation, la présente invention concerne une méthode de traitement de maladies liées à l'IgE, faisant appel à un agent se fixant sélectivement sur le NNT-1. Dans un autre mode de réalisation, la présente invention concerne une méthode de traitement de maladies liées à l'IgE, faisant appel à un agent modulant l'expression du NNT-1. L'invention concerne également des méthodes permettant de moduler les taux d'IgE et de diagnostiquer, prévenir et/ou traiter certains types de maladies allergiques au moyen d'inhibiteurs de NNT-1.
PCT/US2001/025906 2000-08-18 2001-08-17 Methodes et compositions pour traiter des maladies liees a l'ige au moyen d'inhibiteurs du nnt-1 WO2002015977A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MXPA03001434A MXPA03001434A (es) 2000-08-18 2001-08-17 Metodos y composiciones para el tratamiento de la enfermedad relacionada con la inmunoglobulina e, utilizando inhibidores del factor neutrofico 1 novedoso.
CA002419274A CA2419274A1 (fr) 2000-08-18 2001-08-17 Methodes et compositions pour traiter des maladies liees a l'ige au moyen d'inhibiteurs du nnt-1
JP2002520896A JP2004513081A (ja) 2000-08-18 2001-08-17 ＮＮＴ−１インヒビターを使用してＩｇＥ関連疾患を治療するための方法および組成物
EP01962255A EP1309374A2 (fr) 2000-08-18 2001-08-17 Methodes et compositions pour traiter des maladies liees a l'ige au moyen d'inhibiteurs du nnt-1
AU2001283451A AU2001283451A1 (en) 2000-08-18 2001-08-17 Methods and compositions for treating igE-related disease using NNT-1 inhibitors
AU2005232321A AU2005232321A1 (en) 2000-08-18 2005-11-14 Methods and compositions for treating IgE-related disease using NNT-1-inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22643600P 2000-08-18 2000-08-18
US60/226,436 2000-08-18
US09/931,704 2001-08-16
US09/931,704 US6849260B2 (en) 2000-08-18 2001-08-16 Methods and compositions for treating IgE-related disease using NNT-1 inhibitors

Publications (2)

Publication Number Publication Date
WO2002015977A2 WO2002015977A2 (fr) 2002-02-28
WO2002015977A3 true WO2002015977A3 (fr) 2002-11-28

Family

ID=26920541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025906 WO2002015977A2 (fr) 2000-08-18 2001-08-17 Methodes et compositions pour traiter des maladies liees a l'ige au moyen d'inhibiteurs du nnt-1

Country Status (7)

Country Link
US (1) US6849260B2 (fr)
EP (1) EP1309374A2 (fr)
JP (1) JP2004513081A (fr)
AU (2) AU2001283451A1 (fr)
CA (1) CA2419274A1 (fr)
MX (1) MXPA03001434A (fr)
WO (1) WO2002015977A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076288A2 (fr) * 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Constructions d'adn pour l'expression a long terme d'adn nu en injection intravasculaire

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033922A1 (fr) * 1997-02-03 1998-08-06 Amgen Inc. Facteur neurotrophique nnt-1
WO1999000415A1 (fr) * 1997-06-30 1999-01-07 Human Genome Sciences, Inc. Cytokine de type cardiotrophine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011682A1 (fr) 1994-10-17 1996-04-25 Hoechst Pharmaceuticals & Chemicals K.K. Composition preventive et remede pour les maladies allergiques de type i
DE69633623T2 (de) 1995-07-17 2005-12-01 Medivir Uk Ltd. Cystein-Protease-Inhibitoren für die Behandlung von allergischen Krankheiten verursacht duch IgE
US5741772A (en) 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
GB9913327D0 (en) 1999-06-08 1999-08-11 Smithkline Beecham Biolog Vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033922A1 (fr) * 1997-02-03 1998-08-06 Amgen Inc. Facteur neurotrophique nnt-1
WO1999000415A1 (fr) * 1997-06-30 1999-01-07 Human Genome Sciences, Inc. Cytokine de type cardiotrophine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SENALDI GIORGIO ET AL: "Regulatory effects of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) on B cell function.", JOURNAL OF IMMUNOLOGY, vol. 168, no. 11, 1 June 2002 (2002-06-01), June 1, 2002, pages 5690 - 5698, XP002207084, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
JP2004513081A (ja) 2004-04-30
EP1309374A2 (fr) 2003-05-14
AU2001283451A1 (en) 2002-03-04
MXPA03001434A (es) 2004-12-13
US6849260B2 (en) 2005-02-01
CA2419274A1 (fr) 2002-02-28
AU2005232321A1 (en) 2005-12-01
WO2002015977A2 (fr) 2002-02-28
US20020041873A1 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
WO2003059296A3 (fr) Compositions a base de collagene et procedes d'utilisation
IL159422A0 (en) Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
WO2001076514A3 (fr) Methodes et dispositifs destines au traitement d'os fractures et/ou malades
WO2004075865A3 (fr) Modulation selective d'une activite biologique induite par le recepteur tlr
WO2004113277A3 (fr) Procedes et compositions de traitement de maladies associees aux amyloides
WO2002096272A3 (fr) Element vaso-occlusif implantable absorbable
WO2002074327A3 (fr) Compositions et methodes de traitement de maladies associees aux gonadotrophines
AU2001288628A1 (en) Method and reagents for treatment of skin disorders by modulating the notch pathway
DE69813898D1 (de) Substituierte porphyrinen
WO2003068944A3 (fr) Methodes et compositions permettant de moduler la formation de fibres musculaires de type i a l'aide de pgc-1?-
WO2008016759A3 (fr) Produits anti-âge comprenant des extraits de feuilles de menyanthes trifoliata et procédés d'utilisation de ceux-ci
WO2003032916A3 (fr) Organosulfures inhibiteurs de tyrosine phosphatases
WO2004007743A3 (fr) Utilisation d'acides nucleiques cpg dans les maladies a prions
WO2005016227A3 (fr) Methodes et compositions pharmaceutiques servant a moduler l'activation d'heparanase et leurs utilisations
WO2003059267A3 (fr) INHIBITEURS SELECTIFS DE 11β-HSD ET LEURS PROCEDES D'UTILISATION
FI20010392L (fi) Menetelmä kanavasimulaation suorittamiseksi ja kanavasimulaattori
WO2002039122A3 (fr) Compositions et methodes permettant l'identification, l'evaluation, la prevention et la therapie des maladies cardio-vasculaires
DE69943222D1 (de) Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
AU2001251507A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
WO2004053078A3 (fr) Methodes de modulation de l'activite ikk?
WO2002015977A3 (fr) Methodes et compositions pour traiter des maladies liees a l'ige au moyen d'inhibiteurs du nnt-1
WO2002066068A3 (fr) Procédé
ZA200206252B (en) Method and compositions for treating an inflammatory disease.
AU2001256998A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
AU2001251508A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2419274

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/001434

Country of ref document: MX

Ref document number: 2001962255

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002520896

Country of ref document: JP

Ref document number: 2001283451

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001962255

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载